SCHEMBL4469949

SCHEMBL4469949

Cc1ccc(Cl)c(-c2ccc(CN3CCN[C@H](Cc4ccccc4)C3)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.58
LTA4H P09960 1/20 0.47
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
BCHE P06276 3/20 0.39
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39
SIGMAR1 Q99720 2/20 0.39
TACR1 P25103 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
PDE2A O00408 1/20 0.37
GRM2 Q14416 1/20 0.36
CYP46A1 Q9Y6A2 1/20 0.36
KDM1A O60341 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472810 1.00 CNR2 (0.58) CNR2LTA4HLMNAPOLBBCHE
SCHEMBL4473200 1.00 CNR2 (0.58) CNR2LTA4HLMNAPOLBBCHE
SCHEMBL4465717 0.91 LTA4H (0.47) CNR2LTA4HLMNAPOLBBCHE
SCHEMBL4476012 0.91 LTA4H (0.47) CNR2LTA4HLMNAPOLBBCHE
SCHEMBL4465711 0.91 LTA4H (0.47) CNR2LTA4HLMNAPOLBBCHE
SCHEMBL4477113 0.89 LTA4H (0.48) CNR2LTA4HBCHEACHEBACE1
SCHEMBL4649543 0.89 LTA4H (0.48) CNR2LTA4HBCHEACHEBACE1
SCHEMBL4474488 0.89 LTA4H (0.48) CNR2LTA4HBCHEACHEBACE1
SCHEMBL4474543 0.87 CNR2 (0.54) CNR2LTA4HPOLBSIGMAR1TACR1
SCHEMBL4472251 0.87 CNR2 (0.54) CNR2LTA4HPOLBSIGMAR1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
EP-1966132-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-10 EP disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885LTA4H 1547/4885LMNA 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.